ViroGates A/S (Birkerod, Denmark) has patented a method of diagnosing and/or prognosticating HIV infection in a subject comprising the steps of: (a) performing in vitro a measurement of the level of a marker in the form of (i) urokinase plasminogen activator receptor (uPAR), (ii) soluble urokinase plasminogen activator receptor (suPAR), (iii) urokinase-type plasminogen activator (uPA), (iv) one or more degradation products of (i), (ii) or (iii), and/or (v) an mRNA for (i), (ii) or (iii), in a biological fluid sample from a subject, and (b) using the measurement value obtained to evaluate the state of the subject.
With the advent of thrombolytic agents such as urokinase and recombinant tissue plasminogen activator (tPA), a series of promising experimental and clinical studies began to demonstrate the therapeutic benefit of intraventricular administration of fibrinolytic agents for the treatment of IVH.
When the problem is caused by thrombus or fibrin, urokinase (Abbokinase, Abbott Laboratories), a drug made from human kidney cells, has become the drug of choice.
A recent economic study that was presented at this years annual American College of Cardiology conference compared the rheolytic system to therapy with urokinase (Abbott Park, IL-based Abbott Laboratoriess Abbokinase) and reported that rheolytic thrombectomy saved more than $3,500 per patient in reduced hospital stays, doctors fees, and other costs.
``He has trouble seeing to one side and he walks with a cane, but he's a rancher, and he's back doing what ranchers do,'' eight months after the drug urokinase was administered to dissolve the clot and restore healthy blood flow to the brain, Clark said.
